BRITISH MEDICAL BULLETIN

VOLUME THIRTY-SIX
1980

CHEMICAL CARCINOGENESIS

Scientific Editor . . . . . P BROOKES

★

THE MUSCULAR DYSTROPHIES

Scientific Editors . . . . . J N WALTON & F L MASTAGLIA

★

DIAGNOSTIC IMAGING

Scientific Editor . . . . . L KREEL

★

MEDICAL DEPARTMENT · THE BRITISH COUNCIL · 65 DAVIES STREET · LONDON · W1Y 2AA

CONTENTS OF VOLUME THIRTY-SIX

NUMBER 1. *Chemical Carcinogenesis*

Scientific Editor: P BROOKES

		PAGE
Introduction	*P Brookes*	1
The history and future of chemical carcinogenesis	*E Boyland*	5
The metabolic activation of chemical carcinogens	*Peter Sims*	11
DNA as a target of alkylating carcinogens	*P D Lawley*	19
Cellular responses to carcinogen-induced DNA damage and the role of DNA repair	*John J Roberts*	25
In-vivo–in-vitro analysis of ethylnitrosourea-induced brain carcinogenesis in the rat	*Joan P Roscoe*	33
Multistage carcinogenesis in the urinary bladder	*R M Hicks*	39
Carcinogenesis by fungal products	*R C Garner*	47
Carcinogenesis and mineral fibres	*J C Wagner, G Berry & F D Pooley*	53
Bacterial mutation as an indicator of carcinogenicity	*S Venitt*	57
Carcinogenic synergism and its reflection in vitro	*John Ashby & J A Styles*	63
Interactions between carcinogens and proteins	*B Ketterer*	71
Bracken fern and papilloma virus in bovine alimentary cancer	*William F H Jarrett*	79
Antigenic changes in chemical carcinogenesis	*M J Embleton & R W Baldwin*	83
Bacterial metabolism and human carcinogenesis	*M J Hill*	89
Chemical carcinogenesis: whither epidemiology?	*Michael Alderson*	95
Notes on Contributors		101
Book Reviews		103

NUMBER 2. *The Muscular Dystrophies*

Scientific Editors: J N WALTON & F L MASTAGLIA

		PAGE
Introduction	*J N Walton*	105
Clinical and genetic studies		
Clinical features and classification of the muscular dystrophies	*David Gardner-Medwin*	109
Duchenne muscular dystrophy: genetic aspects, carrier detection and antenatal diagnosis	*Alan E H Emery*	117
Clinical biochemistry of muscular dystrophy	*R J T Pennington*	123
Electrodiagnosis of the muscular dystrophies	*Michael Hayward*	127
The heart in muscular dystrophy	*Stewart Hunter*	133
The respiratory system in muscular dystrophy	*J Newsom-Davis*	135
Management of muscular dystrophy: pharmacological and physical aspects	*V Dubowitz & J Heckmatt*	139
Pathogenesis and current trends in research		
Morphological changes in dystrophic muscle	*M J Cullen & F L Mastaglia*	145
Skeletal muscle: regeneration and transplantation studies	*J C Sloper & T A Partridge*	153
Studies of muscular performance in normal and dystrophic subjects	*R H T Edwards*	159
Intermediary metabolism of muscle in Duchenne muscular dystrophy	*David A Ellis*	165
Muscle cell differentiation and the prospects for genetic engineering	*K W Jones*	173

Tissue culture of dystrophic muscle cells *E J Thompson* 181
Is there a membrane defect in muscle and other cells? *J A Lucy* 187
Animal models: what is their relevance to the pathogenesis of human muscular dystrophy? *J B Harris & C R Slater* 193
Future prospects *A F Huxley* 199
Notes on Contributors 201
Book Reviews 204

NUMBER 3. *Diagnostic Imaging*

Scientific Editor: L KREEL

PAGE

Introduction *L Kreel* 205
Tumour localization *V Ralph McCready* 209
Dynamic radionuclide imaging *Keith E Britton* 215
Radionuclide emission imaging: single-photon techniques including radiopharmaceutical developments *P P Dendy, P F Sharp, W I Keyes & J R Mallard* 223
Positron emission tomography and measurements of regional tissue function in man *Terry Jones* 231
Nuclear medicine in clinical cardiology *M N Maisey, D A Brennand-Roper & R J Wainwright* 237
Doppler ultrasound in clinical diagnosis *J P Woodcock* 243
Ultrasound in obstetrics and gynaecology: recent developments *J P Neilson & Valerie D Hood* 249
Abdominal ultrasound diagnosis *P N T Wells* 257
Cardiac ultrasound *J Christine Rodger* 261
New developments in ultrasonic equipment *A J Hall* 267
Developments in contrast media applied to neuroradiology *Brian E Kendall* 273
The validity and use of computed tomography attenuation values *G Williams, G M Bydder & L Kreel* 279
Recent technical developments in *x*-ray computed tomography and digital radiography *R P Parker* 289
Bone density measurement with computed tomography *Urs Elsasser & Jonathan Reeve* 293
Nuclear magnetic resonance imaging *W S Moore & G N Holland* 297
Notes on Contributors 301
Book Reviews 303

INDEX TO VOLUME THIRTY-SIX

Names printed in capitals are those of authors who have contributed papers. Titles of books are printed in italics.

A

Abdomen, fluid collection, computed tomography attenuation values in, 282
—positron emission tomography, 235
—ultrasonography, 257
2-Acetylaminofluorene, metabolic activation, 14, 15
Actinolite, 53
Aflatoxin and liver cancer, 93
—B_1, activation, 14, 47
——biological effects, 47
——carcinogenicity, 47
——metabolism, 14, 47
—B_1-oxide, related model compounds, 52
—B_1-8,9-oxide, mutagenicity, 48
——production, species differences, 49
——reaction with nucleic acids, 49
—G_1, activation, 50
ALDERSON M: Chemical carcinogenesis: whither epidemiology? 95
Alimentary carcinoma in cattle, 79
—tract cancer, and bacterial metabolites, 93
Alkylating agents, DNA damage due to, 28
Amino acids, bacterial metabolites with mutagenic, carcinogenic or promoting activity, 89

INDEX TO VOLUME THIRTY-SIX

Amino acids, labelled, in diagnosis of tumours, 209
Amosite, 53
Anthophyllite, 53
Antibiotics, radionuclide-labelled, for tumour localization, 211, 212
Antibodies, radionuclide-labelled, for tumour localization, 211, 212
Antigens, rejection, tumour-associated, 83
—tumour-associated, origin, 85
————possible mechanism of induction, 87
Aorta, abdominal, ultrasonic scanning, 260
Aortic valve, echocardiography, 262
Asbestos, carcinogenicity, 53
——animal experiments, 55
——epidemiological investigations, 54
—types and uses, 53
Ascites, ultrasonic detection, 258
ASHBY J & STYLES J A: Carcinogenic synergism and its reflection in vitro, 63
Attenuation values in computed tomography, validity and use, 279

B

Bacteria, carcinogen production by, 89
—metabolism, and human carcinogenesis, 89
—metabolites, role in human carcinogenesis, 91
—mutation as indicator of carcinogenicity, 57
BALDWIN R W, *see* EMBLETON M J, 83
Becker muscular dystrophy, 111
Benzo[*a*]pyrene, metabolic activation, 12
BERRY G, *see* WAGNER J C, 53
Bile salt metabolism, carcinogenesis promoters, 90
Bilharzia and bladder cancer, 45, 92
Biographical notes on contributors, 101, 201, 301
Biology, submolecular: *Submolecular biology and cancer*, 103
Bladder cancer in bilharzial patients, 45, 92
—carcinogenesis, multistage, 39
—*N*-methyl-*N*-nitrosourea-induced tumour, 40, 42
—response to multiple carcinogenic factors, 41
——to single carcinogens, 39
—ultrasonic scanning, 259
Blood pressure measurement with Doppler ultrasound, 246
Bone, density measurement with computed tomography, 293
—mineral determination by computed tomography, 293
Book reviews, 103, 204, 303
BOYLAND E: The history and future of chemical carcinogenesis, 5
Bracken fern and papilloma virus in bovine alimentary canal, 79
Brain, blood flow, radionuclide studies, 218
—carcinogenesis induced by ethylnitrosourea, in-vivo–in-vitro analysis, 33
—disease, Doppler ultrasound investigation, 245
—lesions, computed tomography attenuation values in, 286
—positron emission tomography, 234
BRENNAND-ROPER D A, *see* MAISEY M N, 237
BRITTON K E: Dynamic radionuclide imaging, 215
BROOKES P: Chemical carcinogenesis. Introduction to symposium, 1
BYDDER G M, *see* WILLIAMS G, 279

C

Cancer: *Cancer registration and its techniques*, 104
—environmental, 9
—epidemiology: *Directory of on-going research in cancer epidemiology*, 104
—statistics: *Cancer registration and its techniques*, 104
——*Report of a WHO/IARC Expert Committee*, 104
—*Submolecular biology and cancer*, 103
Carbonium ions, metabolic formation, 16
Carcinogenesis, bacterial metabolites in, 91
—chemical, 1–104
——antigenic changes in, 83
——future trends, 9
——introduction to symposium, 1
——stages, 7
—epidemiology, future studies, 95
—history, 5
Carcinogenic risks: strategies for intervention, 103
—synergism and its reflection in vitro, 63
—thresholds, 69
Carcinogenicity, in-vitro assays, 63
Carcinogens, alkylating, DNA as target, 19
—bacterial production, 89
—chemical, detection methods, 15
——enzymes involved in activation, 11
——metabolic activation, 7, 11
——potency, 6
——testing procedures, 5
—detection by bacterial mutation tests, 57
—environmental, 9
—interactions with proteins, 71
—lipophilic, transport, effect of intracellular binding proteins, 72
—production by bacteria, 89
Cardiology, clinical, nuclear medicine in, 237
—Doppler ultrasound diagnosis in, 243
Cardiomyopathies, echocardiography, 264
Cardiovascular system, nuclear medical investigation, 237
Cells, malignant, immunological characterization, 85
—response to carcinogen-induced DNA damage, 25
Cerebral flow studies with radionuclides, 218
—ventricular volume, computed tomography attenuation values, 285
Cerebrospinal fluid dynamics, study with contrast media, 274
Cerebrovascular disease, Doppler ultrasound investigation, 245
Cervical cancer and *N*-nitrosamines, 92
Chrysotile, 53
Ciba Foundation: *Submolecular biology and cancer*, 103
Circulatory proteins, interactions with carcinogens, 77
Cisternography, computed, contrast media, 274
Computing principles and techniques, 304
Contrast media in neuroradiology, 273
——iodine-based, in neuroradiology, 273
Contributors, biographical notes on, 101, 201, 301
Coronary artery disease, scintigraphy evaluation, 239
Cox P H (editor): *Progress in radiopharmacology: selected topics*, 305
Creatine kinase, serum level in muscular dystrophy, 118, 120, 123
Crocidolite, 53
CULLEN M J & MASTAGLIA F L: Morphological changes in dystrophic muscle, 145
Cyclamate, dietary, bladder carcinogenesis promoted by, 42
Cyclophosphamide, bladder carcinogenesis promoted by, 44
Cyclotrons, medical, 231
Cytosol binding proteins, interaction with carcinogens, 73

D

Davidson A J, *see* Sherwood T, 305
Davis W & Rosenfeld C (editors): *Carcinogenic risks: strategies for intervention*, 103
DENDY P P, SHARP P F, KEYES W I & MALLARD J R: Radionuclide emission imaging: single-photon techniques including radiopharmaceutical developments, 223
Diagnosis, clinical, use of Doppler ultrasound, 243
Diagnostic imaging, introduction to symposium, 205
7,12-Dimethylbenz[*a*]anthracene, tumours induced by, 42
DNA as target of alkylating carcinogens, 19
—base damage, mutagenic effects, 29
—damage, and cytotoxicity, 29
——carcinogen-induced, cellular responses, 25
——reactions to, relation to carcinogenicity, 28
—effect of chemical carcinogens, 14, 15, 16, 19, 25
—recombinant technology in muscular atrophy, 173
—repair mechanisms after carcinogen-induced damage, 25
Doppler ultrasound in clinical diagnosis, 243
DUBOWITZ V & HECKMATT J: Management of muscular dystrophy: pharmacological and physical aspects, 139
Duchenne muscular dystrophy, 110
————antenatal diagnosis, 120
————birth incidence, 117
————carrier detection, 118
————genetic aspects, 117
————engineering, 173
————intermediary metabolism of muscle in, 165
————morphological studies, 148

INDEX TO VOLUME THIRTY-SIX

E

Echocardiography, 261
—Doppler, 243
EDWARDS R H T: Studies of muscular performance in normal and dystrophic subjects, 159
Electrocardiographic anomalies in muscular dystrophy, 134
Electrodiagnosis of muscular dystrophies, 127
Electromyography in muscular dystrophy, 127
—single-fibre, 131
ELLIS D A: Intermediary metabolism of muscle in Duchenne muscular dystrophy, 165
ELSASSER U & REEVE J: Bone density measurement with computed tomography, 293
EMBLETON M J & BALDWIN R W: Antigenic changes in chemical carcinogenesis, 83
EMERY A E H: Duchenne muscular dystrophy: genetic aspects, carrier detection and antenatal diagnosis, 117
Endocarditis, bacterial, echocardiographic diagnosis, 263
Epoxides, metabolism, 12
Erythrocytes in myotonic dystrophy, 188
Ethylnitrosourea, brain carcinogenesis induced by, in-vivo–in-vitro analysis, 33

F

Fatty acid binding protein, interaction with carcinogens, 72
Fern, bracken, and papilloma virus in bovine alimentary canal, 79
Fetus, abnormality, ultrasonic diagnosis, 249
—dynamic functioning, ultrasonography, 253
—weight estimation by ultrasound, 253
Fungal products, carcinogenesis by, 47

G

Gall-bladder, ultrasonography, 258
Gallium citrate for tumour localization, 212
Gamma camera for radionuclide emission imaging, 224
GARDNER-MEDWIN D: Clinical features and classification of the muscular dystrophies, 109
GARNER R C: Carcinogenesis by fungal products, 47
Gastroenterology, ultrasonic diagnosis in, 257
Gastrointestinal studies using radionuclides, 221
Genito-urinary diseases, ultrasonic diagnosis, 258
Glass, fibrous, 54
Graafian follicles, ultrasonographic assessment, 254
Gynaecology, ultrasound in, 249

H

Haemochromatosis, computed tomography attenuation values in, 283
HALL A J: New developments in ultrasonic equipment, 267
HARRIS J B & SLATER C R: Animal models: what is their relevance to the pathogenesis of human muscular dystrophy? 193
HAYWARD M: Electrodiagnosis of the muscular dystrophies, 127
Heart disease, congenital, echocardiography, 265
——cyanotic, nuclear studies, 238
—Doppler ultrasound investigation, 243
—echocardiography, 261
—in muscular dystrophy, 133
—left ventricular function studies, radionuclides in, 239
—murmurs, nuclear evaluation, 238
—nuclear medical study, 237
—ultrasonic scanning, 261
HECKMATT J, *see* DUBOWITZ V, 139
HICKS R M: Multistage carcinogenesis in the urinary bladder, 39
HILL M J: Bacterial metabolism and human carcinogenesis, 89
HOLLAND G N, *see* MOORE W S, 297
HOOD V D, *see* NEILSON J P, 249
HUNTER S: The heart in muscular dystrophy, 133
HUXLEY A F: [Muscular dystrophy]: future prospects, 199
Hydrocarbons, polycyclic aromatic, metabolism, 12
——DNA damage due to, 29

I

Imaging, diagnostic, 205–306
——introduction to symposium, 205
—electronic: *Electronic imaging*, 304
—medical: *Medical imaging—CT U/S IS NMR: a basic course*, 303
——*Recent advances in radiology and medical imaging, No. 6*, 303
—nuclear magnetic resonance, 297
International Agency for Research on Cancer: *Cancer statistics: Report of a WHO/IARC Expert Committee*, 104
Iodine-based contrast media in neuroradiology, 273
Ioxaglic acid contrast medium in neuroradiography, 276
Isoprenaline, effect on induced bladder tumours, 45

J

JARRETT W F H: Bracken fern and papilloma virus in bovine alimentary cancer, 79
JONES K W: Muscle cell differentiation and the prospects for genetic engineering, 173
JONES T: Positron emission tomography and measurements of regional tissue function in man, 231

K

KENDALL B E: Developments in contrast media applied to neuroradiology, 273
KETTERER B: Interactions between carcinogens and proteins, 71
KEYES W I, *see* DENDY P P, 223
Kidney, radionuclide imaging, 216
—ultrasonic scanning, 259
KREEL L: Diagnostic imaging. Introduction to symposium, 205
—(editor): *Medical imaging—CT U/S IS NMR: a basic course*, 303
—*see* WILLIAMS G, 279

L

LAWLEY P D: DNA as a target of alkylating carcinogens, 19
Ligandin, interaction with carcinogens, 72
Liver cancer and aflatoxin, 93
—fatty infiltration, computed tomography attenuation values in, 283
—radionuclide imaging studies, 219
Lodge T & Steiner R E (editors): *Recent advances in radiology and medical imaging, No. 6*, 303
LUCY J A: Is there a membrane defect in muscle and other cells? 187
Lung densitometry, 286
—positron emission tomography, 235
Lunt G G & Marchbanks R M (editors): *The biochemistry of myasthenia gravis and muscular dystrophy*, 204
Lymph nodes, retroperitoneal, ultrasonic scanning, 260
Lymphoma, thymic, induction by alkylating carcinogens, 21

M

McAlister J M: *Radionuclide techniques in medicine*, 304
McCREADY V R: Tumour localization, 209
McLean T P & Schagen P (editors): *Electronic imaging*, 304
MacLennan R, Muir C, Steinitz R & Winkler A (editors): *Cancer registration and its techniques*, 104
MAISEY M N, BRENNAND-ROPER D A & WAINWRIGHT R J: Nuclear medicine in clinical cardiology, 237
MALLARD J R, *see* DENDY P P, 223
Marchbanks R M, *see* Lunt G G, 204
MASTAGLIA F L, *see* CULLEN M J, 145
3-Methylcholanthrene-induced sarcomas, immunological characterization of malignant cells in, 85
N-methyl-*N*-nitrosourea, bladder tumour induced by, 40
Metrizamide, adverse effects, 275
—contrast medium in neuroradiology, 274
Mineral fibres, carcinogenicity, 53, 55
Mitral valve, echocardiography, 261
MOORE W S & HOLLAND G N: Nuclear magnetic resonance imaging, 297
Motor unit measurements in muscular dystrophy, 128

INDEX TO VOLUME THIRTY-SIX

Muir C S & Wagner G (editors): *Directory of on-going research in cancer epidemiology 1979*, 104
—*see* MacLennan R, 104
Muscle, breakdown and repair, relation to function, 161
—bulk as determinant of contraction force, 161
—cell differentiation, and genetic engineering, 173
—cells, dystrophic, tissue culture, 181
——membrane defect in, 187
—contraction force, clinical measurement, 159
—dystrophic, morphological changes, 145
—metabolism, intermediary, in Duchenne muscular atrophy, 165
—performance in normal and dystrophic subjects, 159
—protein synthesis, control in muscular dystrophy, 162
—regeneration in Duchenne dystrophy, 154
——in grafts, 156
—skeletal, force-generating capacity, 160
——regeneration studies, 153
——transplantation studies, 153
Muscular dystrophies, 105–204
——aetiology, hypotheses, 194
——Becker, 111
——benign X-linked, 111
——biochemistry, clinical, 123
———*Biochemistry of myasthenia gravis and muscular dystrophy*, 204
——blood cell changes in, 125
——cardiac involvement, 133
——childhood, with autosomal recessive inheritance, 112
——classification, 109
——ciinical features, 109
——congenital, 113
——control of muscle protein synthesis in, 162
——deformities in, prevention, 141
——distal (adult onset), 114
———(juvenile onset), 114
——Duchenne, 110
———antenatal diagnosis, 120
———birth incidence, 117
———carrier detection, 118
———genetic aspects, 117
————engineering, 173
———intermediary muscle metabolism in, 165
———morphological studies, 148
——electrodiagnosis, 127
——facioscapulohumeral, 113
——future prospects in research and treatment, 199
——introduction to symposium, 105
——management, pharmacological aspects, 139
———physical aspects, 141
——membrane defect in muscle cells, 187
——morphology, 145
——myotonic, 114
——occurrence in animals, 193
——ocular, 114
——oculopharyngeal, 114
——pathogenesis, relevance of animal models, 193
——pathophysiology as related to muscle performance, 162
——proximal, of late onset and autosomal dominant inheritance, 114
——respiratory muscle weakness in, 135
——scapulohumeral, 112
——therapeutic trials, 141
——tissue culture of cells, 181
——urinary excretion changes, 125
Myasthenia gravis: *Biochemistry of myasthenia gravis and muscular dystrophy*, 204
Myelography, computed, contrast media, 274
Myocardial infarction, detection with radionuclides, 240
Myocardium, involvement in muscular dystrophy, 133
—perfusion scintigraphy, 239
—positron emission tomography, 235
Myoglobin serum level in muscular dystrophy, 124
Myopathy, hereditary, limited to females, 112
—scapuloperoneal, autosomal dominant, 113
——X-linked, 111
Myotonic dystrophy, morphological muscle changes, 149

N

Naphthalene, metabolism, 12
NEILSON J P & HOOD V D: Ultrasound in obstetrics and gynaecology: recent developments, 249
Neoantigen expression as response to carcinogen, 84
Nerve conduction measurements in muscular dystrophy, 127
Neuroradiology, contrast media, 273
NEWSOM-DAVIS J: The respiratory system in muscular dystrophy, 135
Nitrate, relation to gastric cancer, 91
Nitro compounds, aromatic, carcinogenic, activation, 15
N-(4-(5-nitro-2-furyl)-2-thiazolyl)formamide, bladder tumours induced by, 40, 43
N-Nitroso compounds, formation by bacterial metabolism, 90
N-Nitrosoamines and bladder cancer in bilharzial patients, 92
—and cervical cancer, 92
Nuclear magnetic resonance imaging, 297
—medicine in clinical cardiology, 237
—proteins and carcinogen binding, 76

O

Obstetrics, ultrasound in, 249
Ocular muscular dystrophy, 114
Oculopharyngeal muscular dystrophy, 114
Oncology, applications of computed tomography in, 291
Osteoporosis, applications of computed tomography in, 295
—treatment, 295

P

Pancreas, ultrasonography, 258
Papilloma virus in bovine alimentary canal, association with bracken fern, 79
PARKER R P: Recent technical developments in *x*-ray computed tomography and digital radiography, 289
PARTRIDGE T A, *see* SLOPER J C, 153
PENNINGTON R J T: Clinical biochemistry of muscular dystrophy, 123
Pericardial effusion, echocardiographic diagnosis, 265
Pharmaceutical Codex, Incorporating the British Pharmaceutical Codex, 11th ed., 204
Pharmacology: *Progress in radiopharmacology: selected topics*, 305
Photon techniques in radionuclide emission imaging, 223
Physiology, clinical: *Non-invasive physiological measurements, vol. 1*, 306
Placenta, ultrasonography, 253
POOLEY F D, *see* WAGNER J C, 53
Positron camera, 232
—coincidence detection, 232
—emission tomography, 231
——transaxial tomography, 232, 233
Pregnancy, ultrasonic scanning in, 249
Prostate, ultrasonic scanning, 259
Proteins, interactions with carcinogens, 71
Pulmonary valve, echocardiography, 263
Pyruvate kinase, serum level in muscular dystrophy, 124

R

Radiography, digital, recent technical developments, 289, 292
Radiology: *Recent advances in radiology and medical imaging, No. 6*, 303
—*Uroradiology*, 305
Radionuclide emission imaging, 223
———data processing and display, 224
—for positive tumour localization, 210
—imaging, dynamic, 215
—*Radionuclide techniques in medicine*, 304
Radiopharmaceuticals for negative tumour localization, 209
—for positive tumour localization, 210
Radiopharmacology: *Progress in radiopharmacology: selected topics*, 305
REEVE J, *see* ELSASSER U, 293
Respiratory system in muscular dystrophies, 135
ROBERTS J J: Cellular responses to carcinogen-induced DNA damage and the role of DNA repair, 25
RODGER J C: Cardiac ultrasound, 261
Rolfe P (editor): *Non-invasive physiological measurements, vol. 1*, 306
ROSCOE J P: In-vivo–in-vitro analysis of ethylnitrosourea-induced brain carcinogenesis in the rat, 33
Rosenfeld C, *see* Davis W, 103

S

Saccharin, dietary, bladder carcinogenesis promoted by, 42
Safrole, carcinogens from, 15
Salmonella typhimurium, mutagenicity of aflatoxin B_1 towards, 48, 49, 51

Sarcoma, induction by subcutaneous injection of compounds, 8
Scanners, computed tomography, 289
—Doppler, 270
—duplex, 270
—for radionuclide emission imaging, 223
—phased-array, 269
—real-time linear-array, 267
———mechanical, 268
—static B, 269
—three-dimensional, 271
—ultra-fast, 291
—water-bath, 270
Scapuloperoneal myopathy, autosomal dominant, 113
——X-linked, 111
Schagen P, *see* McLean T P, 304
Schistosoma haematobium infestation, effect on bladder cancer incidence, 45
SHARP P F, *see* DENDY P P, 223
Sherwood T, Davidson A J & Talner L B: *Uroradiology*, 305
SIMS P: The metabolic activation of chemical carcinogens, 11
SLATER C R, *see* HARRIS J B, 193
SLOPER J C & PARTRIDGE T A: Skeletal muscle: regeneration and transplantation studies, 153
Spleen, ultrasonography, 258
Steiner R E, *see* Lodge T, 303
Steinitz R, *see* MacLennan R, 104
Stomach, cancer, causation, 91
STYLES J A, *see* ASHBY J, 63

T

Talner L B, *see* Sherwood T, 305
Technetium-*99m*-labelled compounds in negative tumour localization, 209
Testis, ultrasonic scanning, 259
THOMPSON E J: Tissue culture of dystrophic muscle cells, 181
Thymus, lymphoma induction by alkylating carcinogens, 21
Tissue function, regional, measurement by radioisotopic techniques, 231
Tomography, computed, applications in oncology, 291
——in bone density measurement, 289
——in digital radiography, recent technical developments, 289, 292
——scanners, 289
——transmission, future developments, 290
——validity and use of attenuation values, 279
—positron emission, 231
Tremolite, 53
Tricuspid valve, echocardiography, 263
Tryptophan, dietary, bladder carcinogenesis promoted by, 40, 43, 44
Tumours, computed tomography, 291
—localization by radioactive isotopes, 209

U

Ultrasonics, 304
Ultrasound, equipment, new developments, 267
—in abdominal diagnosis, 257
—in cardiac conditions, 261
—in clinical diagnosis, 243
—in obstetrics and gynaecology, 249
Urinary excretion changes in muscular dystrophy, 125
Urology: *Uroradiology*, 305

V

VENITT S: Bacterial mutation as an indicator of carcinogenicity, 57
Ventricle, left, echocardiography, 263
Vertebrae, bone densitometry, computed tomography attenuation values, 284
Vickery B L: *Computing principles and techniques*, 304
Vinyl chloride, metabolic activation, 17

W

Wagner G, *see* Muir C S, 104
WAGNER J C, BERRY G & POOLEY F D: Carcinogenesis and mineral fibres, 53
WAINWRIGHT R J, *see* MAISEY M N, 237
WALTON J N: The muscular dystrophies. Introduction to symposium, 105
WELLS P N T: Abdominal ultrasound diagnosis, 257
WILLIAMS G, BYDDER G M & KREEL L: The validity and use of computed tomography attenuation values, 279
Winkler A, *see* MacLennan R, 104
WOODCOCK J P: Doppler ultrasound in clinical diagnosis, 243
—*Ultrasonics*, 304
World Health Organization: *Cancer statistics: Report of a WHO/IARC Expert Committee*, 104

X

X-ray computed tomography, 289
Xenon, use in computed tomography of nervous system, 277

ISSN: 0007-1420

Printed in Great Britain by Spottiswoode Ballantyne Ltd., Colchester and London